



BEYOND BATTEN DISEASE
FOUNDATION

Research Grant Application

Type the
Proposal title
here

Applicant Last Name, First Name, Degree

ADMINISTRATIVE PAGES**DATE SUBMITTED**

Name	Month	Day
------	-------	-----

APPLICANT INSTITUTION

Institution	Address Line 1	State
Department	Address Line 2	Country
Division	City	Postal Code
Official signing for applicant institution	Email	

GRANT ACCOUNTING

Authorized Representative	Phone
Email	Telefax
Mailing Address (to send \$ to)	

APPLICANT INFORMATION

Last Name	First	M.I.	Suffix
-----------	-------	------	--------

DESCRIPTIVE TITLE OF APPLICANT'S PROJECT

--

PROPOSED PROJECT

Start Date	End Date
------------	----------

PRINCIPAL INVESTIGATOR CONTACT INFORMATION (PREDOC, POSTDOC, INDEPENDENT INVESTIGATOR)

Position/Title		
Institution	Address Line 1	State
Department	Address Line 2	Country
Division	City	Postal Code

TOTAL PROJECT FUNDING REQUESTED FROM THE BEYOND BATTEN DISEASE FOUNDATION					
OTHER AGENCIES/FOUNDATIONS REVIEWING THIS GRANT					
1.	Date of Review		Date of Notification		
2.	Date of Review		Date of Notification		
3.	Date of Review		Date of Notification		
PROJECT/PERFORMANCE SITE (PRIMARY LOCATION)					
Institution		Address Line 1		State	
Department		Address Line 2		Country	
Division		City		Postal Code	
RESEARCH SUBJECT INFORMATION (US-BASED APPLICANTS ONLY)					
Are human subjects involved?		IRB approval date		Human Subjects Assurance number	
Are vertebrate animals used?		IACUC approval date		Animal Welfare Assurance Number	
REFEREE LIST (LIST EXPERTISE NOT NAMES)					
Disease State Expertise	<i>i.e. JNCL</i>				
Primary Hypothesis Expertise	<i>i.e. Trafficking of CNS (GABA) receptors</i>				
Methods Expertise	<i>i.e. In vivo patch clamp, high throughput small molecule screening, fMRI measures</i>				
Disease State Expertise					
Primary Hypothesis Expertise					
Methods Expertise					

PROPOSAL SUMMARY/ABSTRACT (300 WORDS MAXIMUM)

A Project Summary/Abstract should be a succinct and accurate description of the proposed work when separated from the application. State the hypothesis, specific aims, and methods. Make reference to how the proposal is directly related to the mission of the agency.

BATTEN DISEASE AND RELATED FOUNDATION FUNDING OPTION

If my proposal is deemed meritorious, I agree to have the score and Public Proposal Summary/Abstract reviewed by other Batten, Pediatric, Neurodegenerative/Neurologic and Rare Disease foundations and charities working in partnership with BBDF for consideration for funding. The Public Project Summary/Abstract is a succinct non-proprietary description of the proposed work written by the applicant (page 5). Sharing the score along with a copy of this summary with other foundations will have no effect on this BBDF's consideration for funding of the project but could increase the applicant's overall chances for funding from another agency.

PUBLIC PROPOSAL SUMMARY / ABSTRACT (300 WORDS MAXIMUM)

The Public Summary should be a succinct and accurate description of the proposed work for public dissemination. The applicant is encouraged to copy and paste the summary on page 4 minus any proprietary information. Please do not translate this information into lay language.

**FACILITIES, RESOURCES AND EQUIPMENT RELEVANT TO THE APPLICANT’S PROPOSED LINE OF INQUIRY
(1 PAGE MAXIMUM)**

BIOGRAPHICAL SKETCH OF THE APPLICANT [ADAPTED FROM NIH BIOSKETCH PHS 398/2590 (Rev. 06/09)]
(4 PAGE MAXIMUM)

NAME		POSITION TITLE	
EDUCATION/TRAINING (<i>Begin with baccalaureate or other initial professional education, include postdoctoral training and residency training if applicable.</i>)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YY	FIELD OF STUDY

A. Personal Statement

Briefly describe why your experience and qualifications make you particularly well-suited for your role (e.g., PI, co-PI, co-investigator) in the project that is the subject of the application. Within this section you may, if you choose, briefly describe factors such as family care responsibilities, illness, disability, and active duty military service that may have affected your scientific advancement or productivity.

B. Positions and Honors

List in chronological order previous positions, concluding with the present position. List any honors. Include present membership on any Federal Government public advisory committee.

C. Selected Peer-reviewed Publications

We encourage applicants to limit the list of selected peer-reviewed publications or manuscripts in press. Do not include manuscripts submitted or in preparation. You may choose to include selected publications based on recent importance to the field, and/or relevance to the proposed research.

D. Research Support

List both selected ongoing and completed research projects for the past three years (Federal or non-Federally-supported). *Begin with the projects that are most relevant to the research proposed in the application.* Briefly indicate the overall goals of the projects and responsibilities of the key person identified on the Biographical Sketch.

BIOGRAPHICAL SKETCH OF THE APPLICANT (CONTINUED)

Empty area for biographical sketch.

BIOGRAPHICAL SKETCH OF THE APPLICANT (CONTINUED)

Empty area for biographical sketch.

BIOGRAPHICAL SKETCH OF THE APPLICANT (CONTINUED)

RESEARCH PROPOSAL

A. INTRODUCTION TO THE APPLICATION (1 PAGE MAXIMUM)

The Introduction should give an overall review of the proposal in such a way as to introduce the topic; setting it into a broad context, gradually narrowing down to the hypotheses to be tested. This section serves a critical function for reviewers who have been recruited for their ability to address key issues (i.e. methods) in your proposal but who may not have a working knowledge of Batten disease. Therefore, BBDF's "Introduction" differs from the current NIH format which instructs applicants to leave this section blank unless they are resubmitting a previous proposal and only then should they use the Introduction to summarize substantial additions, deletions and changes to the original application.

B. SPECIFIC AIMS (1 PAGE MAXIMUM)

C. SIGNIFICANCE, INNOVATION AND APPROACH (6 PAGE MAXIMUM)

Significance. Does the proposed work address a significant question or a critical barrier to progress in NCL research? If the aims of the project are achieved, how will our collective knowledge, technical capability, and/or translational capacity be improved?

Innovation. Does the application challenge and seek to shift current research paradigms by utilizing novel theoretical concepts, approaches or methodologies? If yes, novel to NCL research or novel in a broad sense to be applied to NCL investigation?

Approach. Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Are potential problems, alternative strategies, and benchmarks for success presented?

The three definitions are adapted from NIH enhanced review criteria. After reviewing this information, please delete these definitions giving you more room for this portion of your application.

C. SIGNIFICANCE, INNOVATION AND APPROACH (CONTINUED)

C. SIGNIFICANCE, INNOVATION AND APPROACH (CONTINUED)

C. SIGNIFICANCE, INNOVATION AND APPROACH (CONTINUED)

C. SIGNIFICANCE, INNOVATION AND APPROACH (CONTINUED)

C. SIGNIFICANCE, INNOVATION AND APPROACH (CONTINUED)

D. DRUGGABILITY/POTENTIAL FOR TRANSLATION

Druggability is the suitability of a protein, protein complex, or cellular pathway to be targeted by a drug in a way that will correct disease-causing behavior. The importance of a protein/pathway in the pathology of Batten disease is not sufficient to make it a successful drug target. Please assess the druggability of your cellular target(s).

If you are using an FDA-approved or other compound as a functional probe or for pre-clinical assessment as a therapy, briefly describe the approval status, clinical pharmacology, safety profile and efficacy profile of this compound. If there are many, please limit your description to the closest indication(s) to Batten disease. References and links (i.e. to FDA briefing books) are requested.

Of course, not all research leads to the development of drugs. Gene therapy, stem cell biology and other advancements warrant exploration. If you are investigating these or similar avenues, please discuss the state of translation/regulatory approval/current clinical uses of your approach. Be specific.

E. BIBLIOGRAPHY AND REFERENCES CITED (NO MAXIMUM)

BBDF requests that applicants follow the International Committee of Medical Journal Editors (ICMJE) Uniform Requirements style (aka Vancouver Style) for references used by the US National Library of Medicine (NLM) and over 1200 journals <http://www.ncbi.nlm.nih.gov/books/NBK7256/?depth=2>, or the American Medical Association (AMA) Manual of Style <http://www.amamanualofstyle.com/oso/public/index.html>.

**F. EXPECTED OUTCOMES, POSSIBLE PITFALLS AND ALTERNATIVE STRATEGIES
(1 PAGE MAXIMUM)**

G. ASPECTS ESPECIALLY WORTHY TO BE FUNDED (1 PAGE MAXIMUM)

Please describe the contributions of your research project to understanding NCL disease, treatment, prevention or other issues relevant to the mission of the Beyond Batten Disease Foundation that make it especially worthy of funding.

This section provides applicants and reviewers the chance to advocate for the work proposed. All too often review scores aggregate between the fundable and not fundable range suggesting the work proposed is neither good nor bad but just "ok." BBDF has lofty goals that cannot be reached by funding work that is "ok."

H. ITEMIZED AND JUSTIFIED BUDGET (1 PAGE MAXIMUM)

(Facilities and Administration, Indirect, travel and publications costs are not permitted)

Empty area for itemized and justified budget.

ACKNOWLEDGEMENTS AND CHECKLIST

Please go through the following checklist before submitting your application.

- I agree to email my application to dkerkovich@beyondbatten.org
- I understand that, in order to be eligible for funding, all progress reports and other requirements for previous and ongoing BBDF-funded activity, must be complete prior to review.
- If funded, I agree to disclose to BBDF research activity directly stemming from foundation funding.
- I have read BBDF's sharing policy (below) and agree to provide this information according to just-in-time guidelines as a condition of foundation funding the development of research tools
- I hereby certify that the information provided in this application is, to the best of my knowledge, true and correct. I have not knowingly withheld any facts or circumstances that could otherwise jeopardize consideration of this application.

BEYOND BATTEN DISEASE FOUNDATION SHARING POLICY

Limited availability of platform technology such as animal models and cell lines can inhibit the timely development of new knowledge and their application to medical practice. Therefore, applicants must share their plan for depositing foundation-supported resources into a repository center and/or the commercial sector making them available to the broader research community, either before or immediately after publication as a condition of funding the development of these resources. Applicants are asked to use NIH Example Plans for Sharing of Model Organisms http://grants.nih.gov/grants/policy/model_organism as a guide.

**** Please note that this is a just-in-time requirement of funding that must be completed prior to the release of funds. BBDF needs this information but does not require it with your application.**